Cortexyme, Inc. (CRTX): Price and Financial Metrics


Cortexyme, Inc. (CRTX): $2.40

0.13 (+5.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CRTX Stock Price Chart Interactive Chart >

Price chart for CRTX

CRTX Price/Volume Stats

Current price $2.40 52-week high $40.66
Prev. close $2.27 52-week low $2.22
Day low $2.23 Volume 443,600
Day high $2.43 Avg. volume 680,345
50-day MA $3.23 Dividend yield N/A
200-day MA $10.73 Market Cap 72.36M

Cortexyme, Inc. (CRTX) Company Bio


Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases.


CRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CRTX Latest Social Stream


Loading social stream, please wait...

View Full CRTX Social Stream

Latest CRTX News From Around the Web

Below are the latest news stories about Cortexyme Inc that investors may wish to consider to help them evaluate CRTX as an investment opportunity.

Short Sellers Were Right About These 10 Stocks

In this article, we discuss the 10 stocks that short sellers were right about. If you want to skip our detailed analysis of these stocks, go directly to Short Sellers Were Right About These 5 Stocks. Short-sellers were the headliners of early 2021. A year later, these short-sellers are once again in the spotlight amid […]

Yahoo | February 24, 2022

Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks

Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | February 18, 2022

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

NewMediaWire | February 16, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $CRTX #CRTX--The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Business Wire | February 14, 2022

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation CRTX

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cortexyme securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Business Wire | February 14, 2022

Read More 'CRTX' Stories Here

CRTX Price Returns

1-mo -11.44%
3-mo -61.10%
6-mo -81.28%
1-year -86.59%
3-year -83.06%
5-year N/A
YTD -80.98%
2021 36.29%
2020 -50.52%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6335 seconds.